ConductScience.org, home

Paper38579288

IL-18-secreting multiantigen targeting CAR T cells eliminate antigen-low myeloma in an immunocompetent mouse model.

Ng BD and 15 others. Blood, 2024. Cited by 36 papers, by iCite.

Cite this record

ConductScience Library. IL-18-secreting multiantigen targeting CAR T cells eliminate antigen-low myeloma in an immunocompetent mouse model. Papers, record 38579288. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/38579288

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
IL-18-secreting multiantigen targeting CAR T cells eliminate antigen-low myeloma in an immunocompetent mouse model.
PubMed
Journal
Blood
PubMed
Year
2024
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't, Research Support, N.I.H., Extramural
PubMed
Citations, by iCite
36
iCite
Relative citation ratio, by iCite
3.99, provisional
iCite
Revised in PubMed
2026-10-28
PubMed

Authors16

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

Topics12

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Multiple MyelomaMajor topic
Interleukin-18Major topic
Immunotherapy, AdoptiveMajor topic
B-Cell Maturation AntigenMajor topic
Animals
Mice
Humans
Receptors, Chimeric Antigen
Disease Models, Animal
Antigens, Neoplasm
T-Lymphocytes
Cell Line, Tumor

Source PubMed

Download CSV of topics

Grants10

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
R01 HL164902NHLBI NIH HHSUnited StatesR01HL164902PubMed and NIHNIH RePORTER
P01 CA023766NCI NIH HHSUnited StatesP01CA023766PubMed and NIHNIH RePORTER
R01 HL147584NHLBI NIH HHSUnited StatesR01HL147584PubMed and NIHNIH RePORTER
R35 CA284024NCI NIH HHSUnited StatesR35CA284024PubMed and NIHNIH RePORTER
P50 CA254838NCI NIH HHSUnited StatesP50CA254838PubMed and NIHNIH RePORTER
K08 CA252157NCI NIH HHSUnited StatesK08CA252157PubMed and NIHNIH RePORTER
L30 CA209765NCI NIH HHSUnited StatesL30CA209765PubMed and NIHNIH RePORTER
R01 CA228308NCI NIH HHSUnited StatesR01CA228308PubMed and NIHNIH RePORTER
P30 CA008748NCI NIH HHSUnited StatesP30CA008748PubMed and NIHNIH RePORTER
P01 AG052359NIA NIH HHSUnited StatesP01AG052359PubMed and NIHNIH RePORTER

Download CSV of grants

References90

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
120643337Modular utilization of distal cis-regulatory elements controls Ifng gene expression in T cells activated by distinct stimuli.Immunity2010https://conductscience.org/library/papers/20643337PubMed
228225754Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection.Nature2017https://conductscience.org/library/papers/28225754PubMed
333837065IFNγ Is Critical for CAR T Cell-Mediated Myeloid Activation and Induction of Endogenous Immunity.Cancer Discov2021https://conductscience.org/library/papers/33837065PubMed
4259390634-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors.Nat Med2015https://conductscience.org/library/papers/25939063PubMed
537653344Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma.Nat Med2023https://conductscience.org/library/papers/37653344PubMed
626084029GM-CSF Mouse Bone Marrow Cultures Comprise a Heterogeneous Population of CD11c(+)MHCII(+) Macrophages and Dendritic Cells.Immunity2015https://conductscience.org/library/papers/26084029PubMed
736416874CD19/CD20 Bispecific Chimeric Antigen Receptor (CAR) in Naive/Memory T Cells for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma.Cancer Discov2023https://conductscience.org/library/papers/36416874PubMed
827571406Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies.J Clin Invest2016https://conductscience.org/library/papers/27571406PubMed
932034142CD229 CAR T cells eliminate multiple myeloma and tumor propagating cells without fratricide.Nat Commun2020https://conductscience.org/library/papers/32034142PubMed
1033020647Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial.Nat Med2020https://conductscience.org/library/papers/33020647PubMed
1135017485A BAFF ligand-based CAR-T cell targeting three receptors and multiple B cell cancers.Nat Commun2022https://conductscience.org/library/papers/35017485PubMed
1223640482Transcriptional control of macrophage polarization.Arterioscler Thromb Vasc Biol2013https://conductscience.org/library/papers/23640482PubMed
1311704864Transcriptional regulation of bcl-2 by nuclear factor kappa B and its significance in prostate cancer.Oncogene2001https://conductscience.org/library/papers/11704864PubMed
1419319144The role of TNF superfamily members in T-cell function and diseases.Nat Rev Immunol2009https://conductscience.org/library/papers/19319144PubMed
1537399355Limited efficacy of APRIL CAR in patients with multiple myeloma indicate challenges in the use of natural ligands for CAR T-cell therapy.J Immunother Cancer2023https://conductscience.org/library/papers/37399355PubMed
1625317870Chimeric antigen receptor T cells for sustained remissions in leukemia.N Engl J Med2014https://conductscience.org/library/papers/25317870PubMed
1725319501T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial.Lancet2015https://conductscience.org/library/papers/25319501PubMed
1828928126Chimeric antigen receptor T-cell therapies for multiple myeloma.Blood2017https://conductscience.org/library/papers/28928126PubMed
199325300Purification and characterization of the human interleukin-18 receptor.J Biol Chem1997https://conductscience.org/library/papers/9325300PubMed
2034878825Combining a CAR and a chimeric costimulatory receptor enhances T cell sensitivity to low antigen density and promotes persistence.Sci Transl Med2021https://conductscience.org/library/papers/34878825PubMed

See all 90 referencesDownload CSV of references

Cited by27

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 36 citations.

PMIDTitleJournalYearIn PapersSource
42894261Evolution of CAR-T Therapy: Functional Engineering, Manufacturing Innovation, and Future In Vivo Strategies.Cancer Sci2026https://conductscience.org/library/papers/42894261PubMed
42703556Nanomedicine-Empowered CAR-T Therapy for Multiple Myeloma: Toward Programmable, Durable, and Precision Immunotherapy.Int J Nanomedicine2026https://conductscience.org/library/papers/42703556PubMed
42681665Mechanisms, optimization strategies, and salvage options for CAR-T cell therapy.Biomark Res2026https://conductscience.org/library/papers/42681665PubMed
42527665Stuck in traffic: CART cells targeting the tumor microenvironment in hematological malignancies, current advances and future perspectives.Leukemia2026https://conductscience.org/library/papers/42527665PubMed
42463973Interleukin-18 armours antitumour immune effectors.Nat Rev Immunol2026https://conductscience.org/library/papers/42463973PubMed
42093982Targeting CAR-T cell exhaustion in non-Hodgkin lymphoma: mechanistic insights and emerging clinical strategies.Front Immunol2026https://conductscience.org/library/papers/42093982PubMed
41899506Co-Expression of IL-2 Enhances the Efficacy of FLT3-CAR-γδT Cells in Acute Myeloid Leukemia.Cancers (Basel)2026https://conductscience.org/library/papers/41899506PubMed
41865195Engineering the next generation of cellular therapies for solid tumors: multi-specific armored CARs and TME reprogramming strategies.Clin Transl Oncol2026https://conductscience.org/library/papers/41865195PubMed
41817579The Conflicting Role of Myeloid Cells in CAR T-Cell Therapy.Cancer Res2026https://conductscience.org/library/papers/41817579PubMed
41792262Progress in the development of cytokine armoured CAR T cells.Nat Rev Immunol2026https://conductscience.org/library/papers/41792262PubMed
41751464IL-18-Mediated Tumor Immune Evasion.Curr Issues Mol Biol2026https://conductscience.org/library/papers/41751464PubMed
41728085How can we balance risk and benefit of interleukin-18 armored T cell therapies?Exp Biol Med (Maywood)2026https://conductscience.org/library/papers/41728085PubMed
41631887Cytokine-Engineered Chimeric Antigen Receptor-T Cell Therapy: How to Balance the Efficacy and Toxicity.Adv Sci (Weinh)2026https://conductscience.org/library/papers/41631887PubMed
41562052Serologic IL-18 increase with B-cell IL-18R loss characterizes selective IgA deficiency.Front Immunol2025https://conductscience.org/library/papers/41562052PubMed
41520178IL-18 metabolically reprograms CAR-expressing natural killer T cells and enhances their antitumor activity.Mol Ther2026https://conductscience.org/library/papers/41520178PubMed
41485186Emerging strategies to reduce the side effects of CAR-T cell therapy: focusing on gene editing and nanotechnology.Clin Transl Oncol2026https://conductscience.org/library/papers/41485186PubMed
41419929Next-generation CAR-T cells design: leveraging tumor features for enhanced efficacy.Mol Cancer2025https://conductscience.org/library/papers/41419929PubMed
41415362Armoring STEAP1 CAR T cells with IL-18 potentiates antitumor activity in Ewing sarcoma.bioRxiv2025https://conductscience.org/library/papers/41415362PubMed
41131610CAR-T and CAR-NK cell therapies in AML: breaking barriers and charting the future.J Transl Med2025https://conductscience.org/library/papers/41131610PubMed
40973858Engineering CAR-T cells for solid tumors: bispecific antigen targeting, tumor microenvironment modulation, and toxicity control.Immunol Res2025https://conductscience.org/library/papers/40973858PubMed

See all 27 cited byDownload CSV of cited by

Genes3

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
CD19930PubTator's text mininghttps://conductscience.org/library/genes/930NCBI Gene
NR1I39970PubTator's text mininghttps://conductscience.org/library/genes/9970NCBI Gene
TNFRSF17608PubTator's text mininghttps://conductscience.org/library/genes/608NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/38579288

GET https://conductscience.org/api/papers/v1/38579288/references?page=2